| scholarly article | Q13442814 |
| P50 | author | Krista L Lanctôt | Q42725631 |
| P2093 | author name string | Nathan Herrmann | |
| Roberta W Scherer | |||
| Paul B Rosenberg | |||
| Lea T Drye | |||
| Jacobo E Mintzer | |||
| ADMET Research Group | |||
| David Bachman | |||
| P2860 | cites work | Atypical antipsychotics for aggression and psychosis in Alzheimer's disease | Q24244504 |
| Global prevalence of dementia: a Delphi consensus study | Q24603249 | ||
| “Mini-mental state” | Q25938989 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| The role of dopamine in reward and pleasure behaviour--review of data from preclinical research | Q33214750 | ||
| Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging | Q33899794 | ||
| Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study | Q34100750 | ||
| SSRI-induced apathy syndrome: a clinical review | Q34550478 | ||
| Disorders of diminished motivation | Q34559372 | ||
| Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity | Q34567200 | ||
| Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. | Q51996453 | ||
| Construct validity of various verbal and visual memory tests | Q52014519 | ||
| Group differences in the relationship between apathy and depression. | Q52919968 | ||
| The spectrum of behavioral changes in Alzheimer's disease. | Q53210662 | ||
| Syndromic validity of apathy in Alzheimer's disease. | Q53242142 | ||
| Management of mild to moderate Alzheimer’s disease and dementia | Q59238637 | ||
| The contribution of neuropsychiatric symptoms to the cost of dementia care | Q59238642 | ||
| Functional status and clinical findings in patients with Alzheimer's disease | Q67579318 | ||
| Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients | Q71350263 | ||
| Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients | Q72248828 | ||
| Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison | Q72396152 | ||
| N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury | Q72586741 | ||
| Update 2000. Guidelines for prescribing psychoactive drugs | Q73581620 | ||
| Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials | Q34651137 | ||
| Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. | Q34874501 | ||
| The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial | Q34920191 | ||
| Predictors of institutionalisation in people with dementia. | Q35475991 | ||
| Neuropsychiatric aspects of primary progressive aphasia | Q35485998 | ||
| Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study | Q35676415 | ||
| Citalopram for agitation in Alzheimer's disease: design and methods | Q35905635 | ||
| Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators | Q35923192 | ||
| Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. | Q36994937 | ||
| Apathy: a neuropsychiatric syndrome | Q37062763 | ||
| Behavioral effects of current Alzheimer's disease treatments: a descriptive review | Q37218208 | ||
| Are the available apathy measures reliable and valid? A review of the psychometric evidence | Q37518104 | ||
| Clinical practice guidelines for severe Alzheimer's disease | Q37549302 | ||
| Use of psychostimulants for the elderly | Q37608721 | ||
| Apathy following stroke | Q37764378 | ||
| Differential diagnosis and classification of apathy | Q38137420 | ||
| The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
| Apathy and Parkinson's disease | Q39777480 | ||
| Methylphenidate treatment of negative symptoms in patients with dementia | Q41465137 | ||
| A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease | Q43721304 | ||
| Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia | Q43827160 | ||
| Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. | Q44386563 | ||
| Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. | Q44513123 | ||
| Bupropion in the management of apathy. | Q44858925 | ||
| Diagnostic criteria for apathy in clinical practice. | Q45017995 | ||
| Methylphenidate effect on attention deficit in the acutely brain-injured adult | Q45095447 | ||
| Apathy is not depression | Q45296345 | ||
| Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study | Q46193667 | ||
| Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge | Q46595373 | ||
| Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study | Q46849275 | ||
| Relationships between measures of auditory verbal learning and executive functioning | Q46931635 | ||
| A SPECT study of apathy in Alzheimer's disease | Q48137931 | ||
| Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders | Q48298818 | ||
| An informant-based assessment of apathy in Alzheimer disease | Q48622567 | ||
| Reliability and validity of the apathy evaluation scale | Q48866734 | ||
| Epidemiology of apathy in older adults: the Cache County Study. | Q50687339 | ||
| Design of Depression in Alzheimer's Disease Study-2. | Q50920698 | ||
| Apathy following cerebrovascular lesions. | Q51139357 | ||
| Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. | Q51899215 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dementia | Q83030 |
| P304 | page(s) | 549-559 | |
| P577 | publication date | 2013-01-18 | |
| P1433 | published in | American Journal of Geriatric Psychiatry | Q15752426 |
| P1476 | title | Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). | |
| P478 | volume | 21 |
| Q38391306 | Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials |
| Q38242438 | Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)? |
| Q34380997 | Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial |
| Q36724965 | Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease |
| Q36063264 | Principles and management of neuropsychiatric symptoms in Alzheimer's dementia |
| Q34370011 | Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial |
| Q52646203 | Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. |
| Q47652233 | The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial |
Search more.